Medical Management of Coronary Artery Disease in Patients with Chronic Kidney Disease

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Cardiovascular disease (CVD) is the leading cause of mortality in patients with chronic kidney disease (CKD).
• CKD is a significant risk factor for coronary artery disease (CAD), often considered a CAD risk equivalent.
• Current medical therapy guidelines for CAD are largely based on data from non-CKD populations, with limited evidence for CKD patients.

Purpose of the Study:

• To review the existing evidence on the safety and efficacy of medical therapies for CAD in patients with CKD and end-stage renal disease (ESRD).
• To discuss emerging therapies with potential benefits for cardiovascular risk reduction in the CKD population.
• To emphasize the critical need for dedicated clinical trials in CKD and ESRD populations.

Main Methods:

• Systematic review of current literature on medical therapy for CAD in CKD and ESRD.
• Analysis of data from clinical trials, focusing on efficacy and safety in subgroups of patients with varying degrees of kidney function.
• Exploration of evidence for novel therapeutic agents, including PCSK9 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists.

Main Results:

• Evidence suggests that the efficacy of some standard therapies like aspirin and statins may be reduced in patients with declining estimated glomerular filtration rate (eGFR).
• CKD and ESRD patients face a higher risk of adverse events from certain therapies, potentially limiting their use.
• Emerging therapies show promise for reducing cardiovascular risk in CKD patients, offering potential new treatment avenues.

Conclusions:

• Optimal medical therapy for CAD in CKD and ESRD patients remains largely undefined due to a lack of specific clinical trial data.
• Further dedicated research is essential to establish evidence-based treatment strategies and improve cardiovascular outcomes in this high-risk population.
• Novel therapeutic agents may offer significant benefits, but require rigorous evaluation in CKD populations.